Navigation Links
New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
Date:8/31/2007

CAIRNS, Australia, Aug. 31 /PRNewswire/ --

What and When

Data from a six-month study of ramelteon will be presented in poster format at worldsleep07: The 5th World Congress of the World Federation of Sleep Research and Sleep Medicine Societies to be held in Cairns, Australia September 2-6, 2007. This large clinical study demonstrated that ramelteon was effective in reducing time to fall asleep for up to six months versus placebo in adult patients with chronic insomnia.

A total of 451 patients age 18 or older with chronic insomnia were randomized in this clinical study. Patients were given a nighttime dose of ramelteon 8 mg or placebo for up to 24 consecutive weeks with assessments performed after week one and months one, three, five and six of treatment.

Study results revealed consistent and statistically significant improvements in time to sleep onset using objective assessment via polysomnography -- a test that records brain activity and other body functions during sleep. Long-term use of ramelteon 8 mg was well tolerated and showed no evidence of next-day residual effects, pharmacological tolerance, rebound insomnia or withdrawal symptoms.

Poster 525 will be presented on Monday, September 3, 4:00 - 6:00 p.m.

Australian Eastern Standard Time To arrange an interview with Steven Sainati, please contact Amy Losak at

646-935-3917

Ramelteon is marketed by Takeda Pharmaceuticals North America, Inc. in the United States as ROZEREM(TM)(ramelteon).

About ROZEREM

ROZEREM(TM) (ramelteon) is indicated for the treatment of insomnia characterized by difficulty with sleep onset. ROZEREM can be prescribed for long-term use. ROZEREM is the first and only prescription sleep medication that has shown no evidence of abuse or dependence in clinical studies,* and has not been designated as a controlled substance. With the exception of ROZEREM, all other prescription me
'/>"/>

SOURCE Takeda Pharmaceuticals North America, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014  Hologic, Inc. (NASDAQ: ... , Hologic,s President and Chief Executive Officer, will preside ... October 1, the first day of Breast Cancer Awareness ... Company,s campaign focused on the important benefits of Hologic,s ... the FDA as clinically superior to traditional mammography. ...
(Date:9/30/2014)... , Sept. 30, 2014 Arbor ... Summary Global Markets Direct,s, ,Arbor Pharmaceuticals, ... an overview of the Arbor Pharmaceuticals, LLC.,s pharmaceutical ... comprehensive information on the current therapeutic developmental pipeline ... at various stages, therapeutics assessment by drug target, ...
(Date:9/30/2014)... September 30, 2014 ... the "Glycobiology/Glycomics Market by Product [Enzymes (Glycosyltransferase, Neuraminidase, ... and Reagents], Application (Immunology, Oncology) & by ... published by MarketsandMarkets, provides a detailed overview ... current market trends, and strategies impacting the ...
Breaking Medicine Technology:Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 2Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 3Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4
... 26, 2011 NuMe Health LLC, a biotechnology company ... today announced that it has closed a series A-1 ... chief executive officer.  The $675,000 financing was led by ... a larger series A round. The funds from the ...
... 2011 Reportlinker.com announces that a new ... catalogue: China Cardiac Catheters ... http://www.reportlinker.com/p0575380/China-Cardiac-Catheters-and-Guidewires---Market-Trends-Till-2016.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Surgical_Equipment ... This market report provides vital market data ...
Cached Medicine Technology:NuMe Health Announces Closing of Series A-1 Financing Round 2NuMe Health Announces Closing of Series A-1 Financing Round 3NuMe Health Announces Closing of Series A-1 Financing Round 4NuMe Health Announces Closing of Series A-1 Financing Round 5China Cardiac Catheters and Guidewires - Market Trends Till 2016 2China Cardiac Catheters and Guidewires - Market Trends Till 2016 3
(Date:10/1/2014)... ST. LOUIS, MO (PRWEB) October 01, 2014 ... up for Castlewood Eating Disorder Treatment Center’s first ever charity ... provides grants for people with eating disorders who cannot afford ... Fox Run Golf Club in Eureka, Mo. , The ... time at noon. A reception and award dinner will begin ...
(Date:10/1/2014)... 01, 2014 Beverly Hills licensed Clinical ... is celebrating 20 years of private practice in her ... people to achieve greater joy and fulfillment in their ... warning signs and suggestions for anyone who suspects they ... “Believe it or not, it’s not always easy ...
(Date:10/1/2014)... Innovations announces the upcoming airing of Innovations with ... 20, 2014 at 7:30 a.m. EST/PT via Discovery Channel. ... scenes to learn about Break the Cycle’s comprehensive dating ... help and information Break the Cycle provides to teens ... abuse, how to navigate the legal system, and provides ...
(Date:10/1/2014)... NoteSwift Inc., announced today their new ... and 13.0. NoteSwift is the bridge between the EHR ... and document clinical information at the point of care. ... patient note by more than half – and virtually ... points providers state impedes EHR use according to the ...
(Date:10/1/2014)... Scientists at the University of Western ... immune system proteins has the power to knock out ... of the new study on their website. Click ... in the UWA School of Pathology and Laboratory Medicine ... with mesothelioma with promising results. , “A timed ...
Breaking Medicine News(10 mins):Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2Health News:NoteSwift Joins Allscripts Developer Program 2Health News:NoteSwift Joins Allscripts Developer Program 3Health News:New Mesothelioma Study Says Mice Cured by Immuntherapy “Cocktail”, Reports Surviving Mesothelioma 2
... 5, 2008--Worldwide, an average 95.4 percent of LASIK patients ... first review of the world body of scientific literature, ... announced today. , With 16.3 million patients having ... clinical study and technological innovation behind it, LASIK is ...
... March 7 The rheumatoid arthritis (RA),treatment market, held ... withdrawal of Vioxx and Bextra, is rebounding due to ... to,treat RA topped $12 billion in 2006 and -- ... over 11% a year through 2011,according to a new ...
... Following Bi-Partisan Senate Letter, asks Lawmakers,to Reject Proposed ... Make,Reform Much More Difficult to Achieve, Letter ... WASHINGTON, March 7 The Council for Quality,Respiratory ... leading home oxygen,therapy providers and manufacturers who provide ...
... chief of developmental neurobiology at the Medical College of ... has received the 2008 Mathilde Solowey Lecture Award in ... for Advanced Education in the Sciences, honors young or ... edge, translational and of broad importance. , Dr. Mei ...
... generated by ... physicians in SEMI program, DETROIT, March 7 ... 2.5 million electronic prescriptions written in,the state of Michigan in 2007 ... Initiative (SEMI) -- helping drive,Michigan to fifth in the nation in ...
... Corgenix Medical Corporation,(OTC Bulletin Board: CONX), a ... be exhibiting its AspirinWorks(R) Test at the,American College ... 2008 conference is being held March 12-14 at ... will be on-hand at booth #807 during ACOFP ...
Cached Medicine News:Health News:LASIK patients report more than 95 percent satisfaction rate worldwide 2Health News:LASIK patients report more than 95 percent satisfaction rate worldwide 3Health News:LASIK patients report more than 95 percent satisfaction rate worldwide 4Health News:In Post-Vioxx Era, Biologics are Reviving the Arthritis Treatment Market 2Health News:Bi-Partisan Members of U.S. House of Representatives Formally Oppose Funding Reductions to Medicare's Home Oxygen Benefit 2Health News:Bi-Partisan Members of U.S. House of Representatives Formally Oppose Funding Reductions to Medicare's Home Oxygen Benefit 3Health News:Dr. Mei receives 2008 Mathilde Solowey Lecture Award in Neurosciences 2Health News:Dr. Mei receives 2008 Mathilde Solowey Lecture Award in Neurosciences 3Health News:Southeast Michigan ePrescribing Initiative (SEMI) Drives Michigan into Top Five ePrescribing States Nationally 2Health News:Southeast Michigan ePrescribing Initiative (SEMI) Drives Michigan into Top Five ePrescribing States Nationally 3Health News:Southeast Michigan ePrescribing Initiative (SEMI) Drives Michigan into Top Five ePrescribing States Nationally 4Health News:Southeast Michigan ePrescribing Initiative (SEMI) Drives Michigan into Top Five ePrescribing States Nationally 5Health News:Southeast Michigan ePrescribing Initiative (SEMI) Drives Michigan into Top Five ePrescribing States Nationally 6Health News:Corgenix to Exhibit AspirinWorks(R) Test at 2008 ACOFP Meeting in Denver 2Health News:Corgenix to Exhibit AspirinWorks(R) Test at 2008 ACOFP Meeting in Denver 3
... spill-proof design and effective output, even when ... medical nebulizers are free-standing for easy preparation., ... available., ,All Portex® medication nebulizer products ... feature consistently fine misting and the efficient ...
... Portex® medication nebulizers offer a spill-proof ... up to a 45° angle. All medical ... ,A wide variety of configurations are available., ... latex-free. , ,Portex® medication nebulizers feature ...
... inhalers., ,ACE ensures prompt, effective delivery ... versatile design allows it to be used ... an endotracheal airway or resuscitation bag and ... be used in conjunction with an incentive ...
... can be held at angles up to 45° ... in spill column, finger grooves for a non-slip ... 7 feet of regular oxygen tubing. The ... size and sustain optimum mist concentration at every ...
Medicine Products: